AU3236793A - Recombinant and chimeric antibodies to c-erbB-2 - Google Patents

Recombinant and chimeric antibodies to c-erbB-2

Info

Publication number
AU3236793A
AU3236793A AU32367/93A AU3236793A AU3236793A AU 3236793 A AU3236793 A AU 3236793A AU 32367/93 A AU32367/93 A AU 32367/93A AU 3236793 A AU3236793 A AU 3236793A AU 3236793 A AU3236793 A AU 3236793A
Authority
AU
Australia
Prior art keywords
erbb
recombinant
chimeric antibodies
chimeric
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU32367/93A
Inventor
John W Brandis
Hsiao-Lai C Liu
Michael P McBrogan
Deborah L Parkes
Laura K Shawver
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Berlex Laboratories Inc
Original Assignee
Berlex Laboratories Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Berlex Laboratories Inc filed Critical Berlex Laboratories Inc
Publication of AU3236793A publication Critical patent/AU3236793A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
AU32367/93A 1991-12-12 1992-12-04 Recombinant and chimeric antibodies to c-erbB-2 Abandoned AU3236793A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US808462 1985-12-13
US80846291A 1991-12-12 1991-12-12

Publications (1)

Publication Number Publication Date
AU3236793A true AU3236793A (en) 1993-07-19

Family

ID=25198826

Family Applications (1)

Application Number Title Priority Date Filing Date
AU32367/93A Abandoned AU3236793A (en) 1991-12-12 1992-12-04 Recombinant and chimeric antibodies to c-erbB-2

Country Status (2)

Country Link
AU (1) AU3236793A (en)
WO (1) WO1993012220A1 (en)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3951062B2 (en) 1991-09-19 2007-08-01 ジェネンテック・インコーポレーテッド Expression of antibody fragments with cysteine present at least as a free thiol in E. coli for the production of bifunctional F (ab ') 2 antibodies
AU5098193A (en) * 1992-09-01 1994-03-29 Berlex Laboratories, Inc. Glycolation of glycosylated macromolecules
US6448077B1 (en) * 1994-02-10 2002-09-10 Imclone Systems, Inc. Chimeric and humanized monoclonal antibodies specific to VEGF receptors
US6811779B2 (en) 1994-02-10 2004-11-02 Imclone Systems Incorporated Methods for reducing tumor growth with VEGF receptor antibody combined with radiation and chemotherapy
US5840301A (en) * 1994-02-10 1998-11-24 Imclone Systems Incorporated Methods of use of chimerized, humanized, and single chain antibodies specific to VEGF receptors
US5861499A (en) * 1994-02-10 1999-01-19 Imclone Systems Incorporated Nucleic acid molecules encoding the variable or hypervariable region of a monoclonal antibody that binds to an extracellular domain
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
ZA9811162B (en) 1997-12-12 2000-06-07 Genentech Inc Treatment with anti-ERBB2 antibodies.
MXPA02002037A (en) 1999-08-27 2002-10-31 Genentech Inc DOSAGES FOR TREATMENT WITH ANTI ErbB2 ANTIBODIES.
IL152656A0 (en) 2000-05-19 2003-06-24 Genentech Inc Gene detection assay for improving the likelihood of an effective response to an erbb antagonist cancer therapy
MX2007006057A (en) 2004-11-18 2007-12-10 Imclone Systems Inc Antibodies against vascular endothelial growth factor receptor-1.
KR20190110637A (en) 2005-01-21 2019-09-30 제넨테크, 인크. Fixed dosing of her antibodies
SI1850874T1 (en) 2005-02-23 2014-01-31 Genentech, Inc. Extending time to disease progression or survival in ovarian cancer patients using pertuzumab
CN103432580A (en) 2007-03-02 2013-12-11 健泰科生物技术公司 Predicting response to a HER dimerisation inhibitor based on low HER3 expression
SI2171090T1 (en) 2007-06-08 2013-07-31 Genentech, Inc. Gene expression markers of tumor resistance to her2 inhibitor treatment
US9551033B2 (en) 2007-06-08 2017-01-24 Genentech, Inc. Gene expression markers of tumor resistance to HER2 inhibitor treatment
BRPI0812682A2 (en) 2008-06-16 2010-06-22 Genentech Inc metastatic breast cancer treatment
MX2011009729A (en) 2009-03-20 2011-10-14 Genentech Inc Bispecific anti-her antibodies.
SG176073A1 (en) 2009-05-29 2011-12-29 Hoffmann La Roche Modulators for her2 signaling in her2 expressing patients with gastric cancer
JP5981853B2 (en) 2010-02-18 2016-08-31 ジェネンテック， インコーポレイテッド Neuregulin antagonists and their use in the treatment of cancer
WO2011146568A1 (en) 2010-05-19 2011-11-24 Genentech, Inc. Predicting response to a her inhibitor
US20130245233A1 (en) 2010-11-24 2013-09-19 Ming Lei Multispecific Molecules
JP5766296B2 (en) 2010-12-23 2015-08-19 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Polypeptide-polynucleotide complexes and their use in targeted delivery of effector components
CA2842375A1 (en) 2011-08-17 2013-02-21 Erica Jackson Neuregulin antibodies and uses thereof
WO2013063229A1 (en) 2011-10-25 2013-05-02 The Regents Of The University Of Michigan Her2 targeting agent treatment in non-her2-amplified cancers having her2 expressing cancer stem cells
SG11201402510TA (en) 2011-11-30 2014-06-27 Genentech Inc Erbb3 mutations in cancer
WO2013083810A1 (en) 2011-12-09 2013-06-13 F. Hoffmann-La Roche Ag Identification of non-responders to her2 inhibitors
US20130259867A1 (en) 2012-03-27 2013-10-03 Genentech, Inc. Diagnosis and treatments relating to her3 inhibitors
MX363188B (en) 2012-11-30 2019-03-13 Hoffmann La Roche Identification of patients in need of pd-l1 inhibitor cotherapy.
WO2017194554A1 (en) 2016-05-10 2017-11-16 Inserm (Institut National De La Sante Et De La Recherche Medicale) Combinations therapies for the treatment of cancer

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8928874D0 (en) * 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies

Also Published As

Publication number Publication date
WO1993012220A1 (en) 1993-06-24

Similar Documents

Publication Publication Date Title
AU3236793A (en) Recombinant and chimeric antibodies to c-erbB-2
AU4025193A (en) Humanized C-erbB-2 specific antibodies
AU625613B2 (en) Novel chimeric antibodies
AU645187B2 (en) Freeze-dried preparation containing monoclonal antibody
AU5283893A (en) Recombinant humanized anti-cytomegalovirus antibodies
HU9601574D0 (en) Humanized antibodies and uses thereof
AU5283793A (en) Recombinant specific binding protein
AU4382193A (en) BPI-immunoglobulin fusion proteins
AU3342689A (en) Luminescent chimeric proteins
GB8820099D0 (en) Novel chimeric antibodies
AU4618193A (en) Humanized antibodies
IL100764A0 (en) Monoclonal antibodies to elam-1 and their uses
GB9415380D0 (en) Recombinant antibodies specific for tnf-
AU635996B2 (en) Recombinant human anti-cd18 antibodies
GB9412166D0 (en) Retargetting antibodies
AU3665293A (en) Chimeric toxins binding to the GnRH receptor
AU4271793A (en) Novel polypeptide
AU1025692A (en) Novel chimeric antiidiotypic monoclonal antibodies
AU5647894A (en) Chimeric human interferon-gamma-receptor/immunoglobulin polypeptides
AU7796291A (en) High affinity antibodies to small peptides
AU4889393A (en) Human monoclonal anti-peptide antibody and DNA encoding thereof
AU6059194A (en) Monoclonal antibodies to bovine cytokines
NZ242056A (en) Cd4-like chimeric peptides
GB9220808D0 (en) Antibody genes
EP0491351A3 (en) Chimeric antibodies and their use